These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases. Reinert T; Petersen LMS; Henriksen TV; Larsen MØ; Rasmussen MH; Johansen AFB; Øgaard N; Knudsen M; Nordentoft I; Vang S; Krag SRP; Knudsen AR; Mortensen FV; Andersen CL Int J Cancer; 2022 May; 150(9):1537-1548. PubMed ID: 34994972 [TBL] [Abstract][Full Text] [Related]
3. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694 [TBL] [Abstract][Full Text] [Related]
4. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases. Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868 [No Abstract] [Full Text] [Related]
5. Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases. Bolhuis K; van 't Erve I; Mijnals C; Delis-Van Diemen PM; Huiskens J; Komurcu A; Lopez-Yurda M; van den Broek D; Swijnenburg RJ; Meijer GA; Punt CJA; Fijneman RJA EBioMedicine; 2021 Aug; 70():103498. PubMed ID: 34333237 [TBL] [Abstract][Full Text] [Related]
6. Personalized circulating tumor DNA monitoring improves recurrence surveillance and management after curative resection of colorectal liver metastases: a prospective cohort study. Li Y; Xu J; Hu X; Chen Y; Liu F; Chen Y; Ma X; Dong Q; Sun L; Mo S; Zhang L; He X; Tong S; Wu H; Li W; Cai S; Zhu S; Pan Q; Peng J Int J Surg; 2024 May; 110(5):2776-2787. PubMed ID: 38445460 [TBL] [Abstract][Full Text] [Related]
7. Pre-hepatectomy dynamic circulating tumor DNA to predict pathologic response to preoperative chemotherapy and post-hepatectomy recurrence in patients with colorectal liver metastases. Liu M; Bao Q; Zhao T; Huang L; Zhang D; Wang Y; Yan X; Wang H; Jin K; Liu W; Wang K; Xing B Hepatol Int; 2024 Jun; 18(3):1029-1039. PubMed ID: 38427145 [TBL] [Abstract][Full Text] [Related]
8. Recurrence Prediction by Circulating Tumor DNA in the Patient with Colorectal Liver Metastases After Hepatectomy: A Prospective Biomarker Study. Liu W; Jin KM; Zhang MH; Bao Q; Liu M; Xu D; Wang K; Xing BC Ann Surg Oncol; 2023 Aug; 30(8):4916-4926. PubMed ID: 37219651 [TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis. Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376 [TBL] [Abstract][Full Text] [Related]
10. Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation. Mo S; Ye L; Wang D; Han L; Zhou S; Wang H; Dai W; Wang Y; Luo W; Wang R; Xu Y; Cai S; Liu R; Wang Z; Cai G JAMA Oncol; 2023 Jun; 9(6):770-778. PubMed ID: 37079312 [TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. Henriksen TV; Tarazona N; Frydendahl A; Reinert T; Gimeno-Valiente F; Carbonell-Asins JA; Sharma S; Renner D; Hafez D; Roda D; Huerta M; Roselló S; Madsen AH; Løve US; Andersen PV; Thorlacius-Ussing O; Iversen LH; Gotschalck KA; Sethi H; Aleshin A; Cervantes A; Andersen CL Clin Cancer Res; 2022 Feb; 28(3):507-517. PubMed ID: 34625408 [TBL] [Abstract][Full Text] [Related]
12. Utility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer. Bansal VV; Belmont E; Godley F; Dhiman A; Witmer HD; Li S; Liao A; Eng OS; Turaga KK; Shergill A J Am Coll Surg; 2024 Jun; 238(6):1013-1020. PubMed ID: 38299640 [TBL] [Abstract][Full Text] [Related]
13. Locally performed postoperative circulating tumour DNA testing performed during routine clinical care to predict recurrence of colorectal cancer. Cohen R; Beasley A; McCoy M; Platell C; Meehan K; Gray E; Fuller K ANZ J Surg; 2023 Oct; 93(10):2473-2480. PubMed ID: 36921099 [TBL] [Abstract][Full Text] [Related]
14. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort. Henriksen TV; Demuth C; Frydendahl A; Nors J; Nesic M; Rasmussen MH; Reinert T; Larsen OH; Jaensch C; Løve US; Andersen PV; Kolbro T; Thorlacius-Ussing O; Monti A; Gögenur M; Kildsig J; Bondeven P; Schlesinger NH; Iversen LH; Gotschalck KA; Andersen CL Ann Oncol; 2024 Feb; 35(2):229-239. PubMed ID: 37992872 [TBL] [Abstract][Full Text] [Related]
15. Early Circulating Tumor DNA Dynamics Predict Neoadjuvant Therapy Response and Recurrence in Colorectal Liver Metastases: A Prospective Study. Wang XY; Zhang R; Han JH; Chen SQ; Zhao FL; Chen H; Lin J; Fan J; Zhu WW; Lu L; Chen JH Ann Surg Oncol; 2023 Aug; 30(8):5252-5263. PubMed ID: 37202570 [TBL] [Abstract][Full Text] [Related]
16. The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations. Wong R; Tie J; Lee M; Cohen J; Wang Y; Li L; Ma S; Christie M; Kosmider S; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P Int J Cancer; 2019 Jul; 145(2):540-547. PubMed ID: 30628066 [TBL] [Abstract][Full Text] [Related]
17. Circulating tumor DNA as a prognostic indicator of colorectal cancer recurrence-a systematic review and meta-analysis. Chen Y; Mo S; Wu M; Li Y; Chen X; Peng J Int J Colorectal Dis; 2022 May; 37(5):1021-1027. PubMed ID: 35384496 [TBL] [Abstract][Full Text] [Related]
18. Circulating Tumour DNA as Biomarker for Colorectal Liver Metastases: A Systematic Review and Meta-Analysis. Wullaert L; van Rees JM; Martens JWM; Verheul HMW; Grünhagen DJ; Wilting SM; Verhoef C Cells; 2023 Oct; 12(21):. PubMed ID: 37947598 [TBL] [Abstract][Full Text] [Related]
19. Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases. Nishioka Y; Chun YS; Overman MJ; Cao HST; Tzeng CD; Mason MC; Kopetz SW; Bauer TW; Vauthey JN; Newhook TE; J Am Coll Surg; 2022 Apr; 234(4):474-483. PubMed ID: 35290266 [TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor DNA in Colorectal Cancer Liver Metastasis: Analysis of Patients Receiving Liver Resection and Transplant. Wehrle CJ; Raj R; Aykun N; Orabi D; Stackhouse K; Chang J; Estfan B; Kamath S; Krishnamurthi S; Walsh RM; Kwon DCH; Aucejo F JCO Clin Cancer Inform; 2023 Sep; 7():e2300111. PubMed ID: 37820293 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]